Cardiac I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease
نویسندگان
چکیده
Cardiac I-meta-iodobenzylguanidine (MIBG) uptake was measured in 11 patients with dementia with Lewy bodies (DLB), 10 patients with Alzheimer’s disease (AD), and 10 age matched control subjects. The severity of cognitive impairment and duration of symptoms in patients with DLB matched that in the patients with AD. The heart/mediastinum (H/M) ratio of MIBG uptake in the patients with AD was indistinguishable from that in the control subjects. However, the H/M ratio in all patients with DLB was significantly lower than that in the patients with AD and control subjects (p<0.001). These findings indicate that local myocardial sympathetic nerves are aVected in DLB and that cardiac IMIBG scintigraphy may provide a means of diVerentiating DLB from AD. (J Neurol Neurosurg Psychiatry 2001;70:781–783)
منابع مشابه
Uptake index of 123I-metaiodobenzylguanidine myocardial scintigraphy for diagnosing Lewy body disease
Objective(s): Iodine-123 metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy has been used to evaluate cardiac sympathetic denervation in Lewy body disease (LBD), including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). The heart-tomediastinum ratio (H/M) in PD and DLB is significantly lower than that in Parkinson’s plus syndromes and Alzheimer’s disease. Although this ra...
متن کامل123I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
(123)I-meta-iodobenzylguanidine (MIBG) has become widely applied in Japan since its introduction to clinical cardiology and neurology practice in the 1990s. Neurological studies found decreased cardiac uptake of (123)I-MIBG in Lewy-body diseases including Parkinson's disease and dementia with Lewy bodies. Thus, cardiac MIBG uptake is now considered a biomarker of Lewy body diseases. Although sc...
متن کاملA clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.
OBJECTIVE Scintigraphy with [(123)I]metaiodobenzyl guanidine ([(123)I]MIBG) enables the quantification of postganglionic sympathetic cardiac innervation. Recently, myocardial [(123)I]MIBG scintigraphy has been found to be useful in distinguishing Parkinson's disease, a Lewy body disease, from other akinetic rigid syndromes. Some patients initially diagnosed with dementia of the Alzheimer's type...
متن کاملFilling in the missing puzzle piece between cardiac MIBG scintigraphy findings and Parkinson's disease pathology.
I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy can be used to assess the pathophysiology of postganglionic presynaptic cardiac sympathetic nerve endings and is the most frequently used imaging agent to assess cardiac sympathetic innervation. In 1994, Hakusui et al were the first to report reduced cardiac MIBG and preserved thallium accumulation in Parkinson’s disease (PD). Subsequently,...
متن کاملEarly involvement of sympathetic cardiac nerve endings in a patient with rem sleep behaviour disorders
Background REM sleep behaviour disorder (RBD) is a parasomnia characterized by suppression of muscular atonia and abnormal, often violent, motor behaviours during REM sleep. RBD can be either idiopathic or associated with degenerative disorders, such as dementia with Lewy bodies (LBD), multiple system atrophy (MSA), progressive sopranuclear paralysis (PSP) or Parkinson’s disease (PD). Myocardia...
متن کامل